Detalhe da pesquisa
1.
Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Oncology
; 101(12): 817-821, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591211
2.
Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database.
Clin Drug Investig
; 43(3): 177-184, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780109
3.
Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan.
Sci Rep
; 13(1): 8819, 2023 05 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37258564